Drug Profile
Research programme: cancer therapeutics - Bessor Pharma
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Bessor Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 07 Sep 2016 Preclinical trials in Solid tumours in USA (unspecified route) before September 2016